
Sunvozertinib Granted FDA Accelerated Approval in EGFR Exon 20+ NSCLC
The FDA has given accelerated approval to sunvozertinib (Zegfrovy) for use in adult patients with locally advanced or metastatic non–small lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations following progression on platinum-based chemotherapy.1 …